ABSTRACT
AIM: The main aim of our paper is to contribute to objectification of currently widely discussed results of overall survival (OS), disease free survival (DFS) and time from relapse to tumor progression (TTP) in women with breast cancer. METHODS: Forty consecutive patients fulfilling the eligibility criteria were admitted to the study. Fifty-six women were included in the control group. All patients received 6 cycles of adjuvant intensive cyclic combined chemotherapy with epirubicin 150 mg/m(2) and cyclophosphamide 1250 mg/m(2) (EC) applied each 14 days. To overcome haematological toxicity transplantations of autologous peripheral blood progenitor cells (PBPCs) or whole blood enriched of PBPC were used. RESULTS: We found statistically significant difference in OS regardless of the stage of the disease to the benefit of women treated by intensive cyclic EC chemotherapy when compared with the control group. In evaluation of DFS no statistically significant difference was found in survival between the control group and the group with all stages of the disease. TTP in women without relation to the stage was statistically significantly longer than in the control group. CONCLUSION: In our study intensive cyclic EC chemotherapy did not show better curative effect when compared with conventional dosage chemotherapy.
Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Hematopoietic Stem Cell Transplantation/methods , Adult , Aged , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Blood Transfusion , Breast Neoplasms/mortality , Breast Neoplasms/surgery , Case-Control Studies , Cyclophosphamide/administration & dosage , Disease-Free Survival , Epirubicin/administration & dosage , Female , Follow-Up Studies , Granulocyte Colony-Stimulating Factor/administration & dosage , Hematopoietic Stem Cell Mobilization , Hematopoietic Stem Cell Transplantation/adverse effects , Humans , Leukapheresis , Middle Aged , Neoplasm Staging , Platelet Transfusion , Risk Assessment , Risk Factors , Stem Cells , Survival Analysis , Time Factors , Transplantation, Autologous , Treatment OutcomeABSTRACT
The article presents contemporary TNM classification of malignant ocular tumors. This classification allows to establish the prognosis of the disease correctly and to choose proper treatment strategy. According to this classification, it is possible to compare results of the treatment and to communicate with the doctors and hospitals at the national and international level as well. It is necessary to acquaint the doctors especially in postgraduate courses with this classification, although the malignant ocular tumors represent only 0.2-0.5% of all tumors.
